Apr 1, 2012 · PTEN loss or PI3K/AKT signaling pathway activation correlates with human prostate cancer progression and metastasis. However, in preclinical murine models, deletion of Pten alone fails to mimic the significant metastatic burden that frequently accompanies the end stage of …

PTEN loss or PI3K/AKT signaling pathway activation correlates with human prostate cancer progression and metastasis. However, in preclinical murine models, deletion of Pten alone fails to mimic the significant metastatic burden that frequently accompanies the …

At the molecular level, RNAi-mediated Pten inactivation in RAS-Ink/Arf melanoma cells led to E-cadherin downregulation and AKT2 phosphorylation, accompanying enhanced migration and invasion compared to control cells without Pten knock-down.

Dec 1, 2013 · These data demonstrate that the presence of N/F mutations in the absence of RAS or PTEN abnormalities predicts good outcome in almost 50% of adult T-ALL. Conversely, the absence of N/F or presence of RAS/PTEN alterations identifies the remaining cohort of patients with poor prognosis.

Using Cre-LoxP technology and the Probasin promoter, we combined the loss of Pten ( Ptenfl/fl ), to activate the PI3K signalling pathway, with dominant stabilised β-catenin ( Catnb+/lox (ex3)) and activated K-RAS ( K-Ras+/V12) to aberrantly activate WNT and MAPK signalling, respectively.

Tumors with Pten loss or H-ras activation have different biochemical properties, suggestive of alternative routes to malignancy. These findings in this mouse model have important implications for the rational design of new targeted therapies for human tumors.

Nov 11, 2016 · These results reveal a positive feedback loop connecting Pten and Ras pathways and suggest that FGF-activated Ras–MAPK pathway is an effective therapeutic target for preventing skin tumor induced by aberrant Pten signaling.

MAPK and AKT pathways are frequently co-activated in melanoma through overexpression of receptor tyrosine kinases, mutations in their signaling surrogates, such as RAS and BRAF, or loss of negative regulators such as PTEN.

Apr 1, 2012 · Although RAS activation alone cannot initiate prostate cancer development, it significantly accelerated progression caused by PTEN loss, accompanied by epithelial-to-mesenchymal transition (EMT) and macrometastasis with 100% penetrance.

At the molecular level, RNAi-mediated Pten inactivation in RAS-Ink/Arf melanoma cells led to E-cadherin downregulation and AKT2 phosphorylation, accompanying enhanced migration and invasion compared to control cells without Pten knock-down.